Log in
HomeClass Notes1,200,000CA670,000

PHC320H1 Lecture : A success story

97 views3 pages
azuresquirrel208
11 Apr 2012
School
UTSG
Department
Pharmaceutical Chemistry
Course
PHC320H1
Professor
Giaever

For unlimited access to Class Notes, a Class+ subscription is required.

Document Summary

All blood cells arise from one kind of multipotent stem cell e. g. multipotent hemopoietic stem cell progenitor lymphoid or myeloid progenitor. Type of leukemia depends on defects of specific progenitors. Cancer cells: stem cells/daughter cells fail to differentiation. Leukemia: cancer of blood/bone marrow characterized by abnormal proliferation of blood cells (usually wbcs, leukocytes) Chronic myeloid leukemia (cml: myeloproliferative disorder, median age 53, nonspecific symptoms, hard to detect, massive clonal proliferation of myeloid cells, biphasic: chronic (stable) phase blast phase. Philadelphia chromosome: cml patients have characteristic chromosomal abnormality t(9;22, not present in patient"s normal cells. Acquired genetic abnormality: genetic abnormality causally associated with cml, reciprocal translocation between chromosome 9 and 22, abl chr9, bcr chr 22, fused together, bcr-abl constitutively active tyrosine kinase (fusion gene, abl is a tyrosine kinase. When translocated, it is constitutively active: blast crisis: cml cells acquire secondary genetic abnormalities in addition to.

Get access

Grade+
$40 USD/m
Billed monthly
Grade+
Homework Help
Study Guides
Textbook Solutions
Class Notes
Textbook Notes
Booster Class
10 Verified Answers
Class+
$30 USD/m
Billed monthly
Class+
Homework Help
Study Guides
Textbook Solutions
Class Notes
Textbook Notes
Booster Class
7 Verified Answers

Related Documents

PATH 310 Lecture Notes - Lecture 14: Mesylate, Protein Dimer, Intrinsically Disordered Proteins
raspberryserval319
Pathology 3500 Lecture Notes - Lecture 17: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, B-Cell Chronic Lymphocytic Leukemia
oliveeagle385
LIFESCI 3AA3 Lecture Notes - Lecture 15: Chronic Myelogenous Leukemia, Bone Marrow Examination, Sh3 Domain
silverelk903

Related Questions

"One way to separate a mixture of stem cells and differentiatedcells is to label the cell population with a specific antibody.Let's say stem cells express exactly 100 copies of the membraneantigen X, while all differentiated cells express exactly 10 copiesof X.

To the cell mixture, you add a very large solution of 0.1μMantibody (for X). The Kd (dissociation constant) for theantibody-antigen binding reaction is 1μM (treat antibody as if ithas only one binding site).

1) On average, how many antibody molecules will be bound perstem cell? What about per differentiated cell?

2) Find the standard deviation of the of the number ofantibodies bound per stem cell (assume binomial distribution)

You are working in the lab and discover a new factor (X) that appears to play some important role in wound healing. You are provided with the information that each receptor only binds a single X. In order to better characterize the interaction of X with a putative receptor, you obtain dose- response and binding data on X and obtain the following results:

{[X] } {Bound X (on 10^7 cells)} {Relative rate of proliferation}

0 0 1

10^-12M 0.2 pmols 1.7

10^-11M 1.8 pmols 4.2

10^-10M 6.0 pmols 5.2

10^-9M 10 pmols 5.4

10^-8M 12 pmols 5.4

These are the data you wish to report:
1. Approximate numbers of X receptor molecules per cell

2. Half-maximaldose.

3. Apparent Kd for the X receptor.


4. Any other details that you think might be important.

Write a very concise description containing ALL the information asked and a short paragraph describing why do you think these findings might be interesting.